Three-stage procedures offer an optimal relationship between costs and benefits in analysing genetic influences in diseases and therapies, a fact that has major practical importance for the ever growing number of gene analyses. This finding from a current project by the Austrian Science Fund FWF was presented at the 5th International Conference on Multiple Comparison Procedures (MCP2007) in Vienna, which recently drew to a close. The conference, held at the Medical University, focused on the increasingly important issue of boosting the efficiency of medical studies in statistical terms.
30,000 – this is the number of genes that can be analysed simultaneously with state-of-the-art instruments. Such analyses provide a means of identifying whether individual genes have a decisive impact in the course of a disease or therapy. However, the more genes that are examined in a study, the greater the probability of incorrectly identifying a gene as a factor when, in reality, it has no influence.
MORE CONCENTRATION – LESS ERRORS
Dr. Sonja Zehetmayer from the Department of Medical Statistics, Medical University of Vienna, says: “The problem of identifying factors incorrectly could be countered by a very high number of repetition. However, repetition normally needs to be kept to a minimum, owing to high costs. A more innovative approach to solve this problem is offered by multi-stage methods. These involve preselecting genes following the first examination stage. In subsequent stages, only these selected genes are subject to further analysis. Concentrating on fewer genes thereby cuts error probability.”
The question of exactly how many stages are needed to deliver an optimal cost-benefit ratio has until now remained unresolved. The answer has now been calculated, published, and discussed by Dr. Zehetmayer and her colleagues at the MCP2007 held in Vienna from 8 to 11 July. In actual fact, the solution turned out to be unexpectedly straightforward – three stages deliver the optimal ratio between the accuracy of the results obtained and the costs necessary for this. Although a fourth stage would offer greater accuracy, the resources this would require are out of all proportion to the additional accuracy gained.
Dr. Zehetmayer also found surprising results when she compared two different test designs with each other: “Multi-stage series of tests can be analysed either by integrating the results of all levels or by analysing the results of only the last stage. While the choice of test design for four-stage methods has a marked effect on its statistical characteristics, this effect is mitigated in the case of a three-stage method.”
Dr. Zehetmayer’s colleague Alexandra Goll presented a further aspect contributing to the optimum configuration of test methods at the MCP2007. She showed that the individual stages of multi-stage test methods can be configured very differently without having a major detrimental effect on the accuracy of the end result. This means that initial stages can clearly be more cost-effective if more accurate and more expensive methods are used for the following stages (involving fewer genes).
There is good reason why the latest trends in the statistical analysis of clinical data are being initiated and analysed at the Department of Medical Studies at the Medical University of Vienna. Prof. Peter Bauer published a paper there in 1989 refuting a basic principle of biostatistics that the test design in an ongoing study must not be changed until the end. This evidence is and remains the basis for multi-stage adaptive analytical methods that have recently attracted worldwide research interest due to cost pressures in healthcare and are supported by the FWF in Austria.
Image and text will be available online from Monday, 16th July 2007, 09.00 a.m. CET onwards:
Dr. Sonja Zehetmayer
Medical University of Vienna
Department of Medical Statistics
1090 Vienna, Austria
T +43 / 650 / 742 22 38
Austrian Science Fund FWF:
Mag. Stefan Bernhardt
Haus der Forschung
1090 Vienna, Austria
T +43 / 1 / 505 67 40 – 8111
Copy Editing and Distribution:
PR&D – Public Relations for Research & Development
Campus Vienna Biocenter 2
1030 Vienna, Austria
T +43 / 1 / 505 70 44
Vienna, 16th July 2007